Carrying both COL1A2 and FBN2 gene heterozygous mutations results in a severe skeletal clinical phenotype: an affected family

Jing Chen¹,²†, Qinqin Xiang¹,²†, Xiao Xiao¹,², Bocheng Xu¹,², Hanbing Xie¹,², He Wang¹,², Mei Yang¹,²† and Shanling Liu¹,²†

Abstract

Background: Osteogenesis imperfecta (OI) is the most common monogenic disease of the skeletal system and is usually caused by mutations in the COL1A1 or COL1A2 genes. Congenital contractual arachnodactyly syndrome (CCA) is an autosomal dominant hereditary disease of connective tissue. To date, the FBN2 gene is the only gene reported to cause CCA. Researchers found that COL1A2 and FBN2 are both involved in the extracellular matrix organization pathway. These findings suggest that these two genes play an important role in a similar mechanism and may trigger a synergistic effect.

Methods: Trio-whole-exome sequencing (Trio-WES) was performed to analyse the underlying genetic cause of a proband with OI in a Chinese family. Sanger sequencing was used to validate the mutations in 3 members of the family with OI with varying degrees of severity of skeletal abnormalities and the members with no clinical signs.

Result: A c.3304G > C mutation in the COL1A2 gene (p.Gly1102Arg) and a novel c.4108G > T mutation in the FBN2 gene (p.Glu1370*) were detected in the proband, an affected member of the family. The affected individuals with both mutations present a more severe phenotype, while affected individuals present a milder phenotype if only the mutation in COL1A2 is detected (c.3304G > C). The unaffected individual in this family did not have any mutations in the COL1A2 gene or FBN2 gene.

Conclusion: Our study is the first clinical report to indicate that patients carrying concomitant mutations in both the COL1A2 and FBN2 genes may present with more severe skeletal abnormalities. Furthermore, our study suggests the possibility of synergistic effects between the COL1A2 and FBN2 genes.

Keywords: Osteogenesis imperfecta, Congenital contractual arachnodactyly syndrome, COL1A2, FBN2, Synergistic effect, Whole-exome sequencing

Background

Osteogenesis imperfecta is a genetic disorder of increased bone fragility, low bone mass, and other connective-tissue manifestations. In the majority of cases, osteogenesis imperfecta is caused by mutations in COL1A1 or COL1A2, which are genes that encode the two collagen type I alpha chains [1, 2]. The incidence of osteogenesis imperfecta in newborns in China is approximately 1/15,000–1/77,000 [3]. OI has a variable phenotype, even
among patients in the same family [4–6]. According to clinical presentation, radiographic findings, and family history, \textit{COL1A1/2} osteogenesis imperfecta (\textit{COL1A1/2}-OI) is mainly classified into four types (I-IV) and is usually inherited in autosomal dominant (AD) pattern [4, 7]. OI-I has the mildest phenotype [2]. Patients with OI-II usually die during the perinatal period [8], and OI-III patients have recurrent fractures and severe bone deformation. Patients with mild to moderate bone deformities and short stature are classified as OI-IV; the severity of OI types increases in the order OI-I < OI-IV < OI-III < OI-II [2]. With the constant increase in the number of identified mutations in \textit{COL1A1}, \textit{COL1A2} or other genes, genotype–phenotype correlation have become increasingly pertinent [1]. Contractural arachnodactyly syndrome (CCA) is a rare autosomal dominant connective tissue disease that is characterized by arachnodactyly, contractures of major joints and progressive scoliosis, and its clinical features partially overlap with the phenotype of Marfan syndrome (MFS) [9–11]. The alpha2 chain of the type I collagen (\textit{COL1A2}) and fibrillin-2 (\textit{FBN2}) genes, which are the cause of these two diseases, respectively, are members of the extracellular matrix pathway. This implies that these two genes may be functionally related and may trigger a synergistic effect.

In this report, we first describe a Chinese family in which the proband and his affected father carried heterozygous mutations in the \textit{COL1A2} gene (OMIM: 120160; c.3304G > C; p.Gly1102Arg) and \textit{FBN2} gene (OMIM: 612570; c.4108G > T; p.Glu1370*) that caused a significantly more severe phenotype of OI. The proband’s elder sister, who had a milder clinical phenotype, only carried a mutation in the \textit{COL1A2} gene (OMIM: 120160; c.3304G > C; p.Gly1102Arg).

\section*{Method}

\subsection*{Clinical data}

A 28-year-old female (III4) who was three months pregnant sought genetic counselling and prenatal diagnosis for the foetus in the current pregnancy at West China Second University Hospital, Sichuan University (Chengdu, China). The woman informed the doctor that her family members had skeletal diseases of variable severity. The proband (III5, the pregnant woman’s brother) was a 17-year-old male who had over sixteen fractures after trauma, of which the long bones of the limbs and ribs were usually involved. At the time of examination, he showed short stature, slender upper limbs, slender fingers, severe joint contractures, significant muscle atrophy and severe skeletal deformities and was unable to walk. Their father (II5) had symptoms similar to those of the proband but could walk slowly on crutches. The pregnant woman (III4) had the mildest phenotype in this family. She only had three fractures to date. She presented with only an old fracture of the left elbow and a mild limitation of dorsoextension. Her appearance and height were normal. The pedigree of this family is shown in Fig. 1.

Trio-whole-exome sequencing (Trio-WES) was performed to analyse the underlying genetic cause of the

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig1.png}
\caption{Pedigree of the proband’s family. Pedigree of a four-generation family with recurrent fractures and bone deformity. Generations are shown as I–IV. Squares indicate male, and circles indicate female. Empty symbols indicate unaffected individuals and filled symbols indicate affected individuals. Deceased individuals are indicated by a slash (/), the arrow shows the proband.}
\end{figure}
family. Suspected mutations detected by next-generation sequencing (NGS) were validated by Sanger sequencing.

DNA extraction
Total genomic DNA was extracted from whole blood from the proband and his family members using a DNeasy Blood & Tissue DNA kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.

Exome sequencing and bioinformatic analysis pipeline
To detect the variants carried by the proband, the Nano WES Human Exome V1 (Berry Genomics) was used to capture the sequences. Then, the enriched library was sequenced on a Nova seq 6000 with 150 paired-end reads. The reads were mapped to a human reference genome (hg38) with BWA (v0.7.15). Variant calling was performed by Verita Trekker (v1.2.0.2). During the analysis of the data, we selected the variants if their minor allele frequencies (MAF) were <0.05 in the 1000 Genomes Project (1000G) (http://browser.1000genomes.org), Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/), and gnomAD (http://gnomad.broadinstitute.org/). SNVs with a minor allele frequency (MAF) ≥1% for a dominant inheritance pattern were excluded. For pathogenicity prediction, CADD (https://cadd.gs.washington.edu), SIFT (http://sift.jcvi.org), PolyPhen2 (http://genetics.bwh.harvard.edu/pph2), and Rare Exome Variant Ensemble Learner (REVEL) (https://sites.google.com/site/revelgenomics/) were used. To select disease-causing variants, we referred to the information from the OMIM database (http://www.omim.org), ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar) and Human Gene Mutation Database (http://www.hgmd.org). SNVs were classified into five categories, pathogenic (P), likely pathogenic (LP), uncertain significance (VUS), likely benign (LB) and benign (B), according to the guidelines of the American College of Medical Genetics (ACMG) [12]. ACMG is based on population data, computational and predictive data, functional data, segregation data, de novo data, and allelic data. The detailed process for identifying candidate variants is shown in Additional file 1: Fig. S1.

Sanger sequencing
To validate the disease-causing variants selected, Sanger sequencing was performed using specific PCR primers designed with Primer Premier 5. The sequences of the FBN2 primers used were FBN2-F: 5′-GCAAACCTACCA ATACACTT-3′ and FBN2-R: 5′-CTCCATACGGTTGCA TCTT-3′. The sequences of the COL1A2 primers used were COL1A2-F: 5′-GAACATGCTTCCGTGTA-3′ and COL1A2-R: 5′-CATCAACTTCAATGTCTTGG-3′. PCR products were sequenced using an ABI 3500 Genetic Analyser (Thermo Fisher Scientific) for COL1A2 c.3304G > C and FBN2 c.4108G > T.

Results
Heterozygous mutations of the COL1A2 and FBN2 genes were identified in a family with a skeletal clinical phenotype
A missense mutation in exon 49 of COL1A2 (NM_000089.4; c.3304G > C; p.Gly1102Arg) was detected in the proband (III5); this mutation was inherited from the patient’s affected father (II5). Additionally, a nonsense mutation in exon 32 of FBN2 (NM_001999.4; c.4108G > T; p.Glu1370*) was also detected in the proband; this mutation was also inherited paternally. In other words, both the proband (II5) and his father (II5) had a severe skeletal clinical phenotype and carried concomitant mutations in both the COL1A2 and FBN2 genes. The presence of the mutations was further validated by Sanger sequencing for the proband (II5) and his father (II5) (Figs. 3, 4). However, no mutations were detected in the unaffected mother (II6) (Figs. 3, 4). No other pathogenic or likely pathogenic variants related to the skeletal disorders were detected in the mother. The mutations and clinical data of the patients in the family are shown in Table 1 and Fig. 2. The presence of the mutations was further validated by Sanger sequencing in the affected elder sister (II4), who presented with a milder phenotype. Only the mutation in COL1A2 (c.3304G > C) was detected in the affected elder sister (II4) (Figs. 3, 4).

In silico analysis
The mutation (c.3304G > C) in COL1A2 results in replacement of a highly conserved glycine (polar amino acid) by arginine (basic amino acid). In silico analysis of the COL1A2 mutation (p.Gly1102Arg) indicated that this substitution is disease causing and deleterious, as determined by CADD_Phred, SIFT_pred, Polyphen2_HVAR_pred, and REVEL. A change in the same codon that results in a p.Gly1102Arg substitution had been previously reported as a COL1A2 mutation associated with Osteogenesis imperfecta IV [17]. In addition, multiple sequence alignment of COL1A2 from different species showed the evolutionary conservation of the glycine residue at position 1102 (Fig. 5).

The nonsense mutation (c.4108G > T) in FBN2 (NM_001999.4) results in a premature termination codon at amino acid position 1370 (p.Glu1370*). The probability of loss-of-function intolerance (pLI=0.99) of this mutation was greater than 0.9, revealing that this nonsense mutation was intolerant to loss-of-function (LoF). Furthermore, the NMD_pred forecasted that this nonsense mutation might generate nonmediated decay (NMD).
According to the guidelines of ACMG, the mutation (c.3304G > C) in COL1A2 and the nonsense mutation (c.4108G > T) in FBN2 were both classified as likely pathogenic (LP) and are considered to be the cause of the clinical manifestations in this family.

Table 1  Mutations and clinical features of individuals included in the study

| Symbol | II5 | III5 | III4 | II6 |
|--------|-----|------|------|-----|
| Gene mutation | COL1A2 c.3304G > C | COL1A2 c.3304G > C | COL1A2 c.3304G > C | None |
| FBN2 c.4108G > T | FBN2 c.4108G > T | FBN2 c.4108G > T | FBN2 c.4108G > T | |
| Phenotype | | | | |
| Short stature | +++ (1.1 m*) | +++ (1.1 m) | − (1.56 m) | − (1.54 m) |
| Sclera | − | − | − | − |
| Recurrent fractures | +++ (≥ 10 times) | +++ (≥ 16 times) | + (3 times) | − |
| Scoliosis | + | + | − | − |
| Acromacia | + | + | − | − |
| Joint contracture | ++ | ++ | − | − |
| Muscle hypotrophy | ++ | ++ | − | − |
| Intellectual development or other systems | − | − | − | − |

Symbol +/−/− indicates whether there is a clinical phenotype, the number of + indicates the severity of the phenotype

*m: meter

Fig. 2 The clinical symptoms of proband's family. A The proband showed short stature, barrel chest, kyphosis, slender fingers and other skeletal deformities. B The proband's father showed similar symptoms to the proband. C The proband's sister had the mildest skeletal system abnormality, and from left to right is the proband, the proband's mother, the proband's sister and the proband's father.
The COL1A2 gene encodes the pro-alpha2 chain of type I collagen, whose triple helix comprises two alpha1 chains and one alpha2 chain [13]. Mutations in COL1A2 are associated with osteogenesis imperfecta types II-IV, Ehlers–Danlos syndrome, and idiopathic osteoporosis. Wenstrup et al. identified the same heterozygous mutation (c.3304G > C) of COL1A2 in a family with an autosomal dominant form of mild-moderate osteogenesis imperfecta. The affected members of this family had bone fragility, short stature and dentinogenesis imperfecta but had no clinical manifestations of slender fingers and severe joint contractures [14]. In this report, the proband, his affected father and less affected sister all carried the same mutation (c.3304G > C) of the COL1A2 gene, and the proband
and his father had slender fingers and severe joint contracture. This phenotype is not consistent with the phenotypes of osteogenesis imperfecta or Ehlers–Danlos syndrome and cannot be explained by genetic heterogeneity. It is likely that the clinical variation among the affected and less affected members of this family results from synergistic effects with other genes involved in matrix production.

\( \text{FBN2} \) is an extracellular matrix gene that encodes fibrillin 2. It is a component of connective tissue microfibrils and may be involved in elastic fibre assembly [15, 16]. Mutations in \( \text{FBN2} \) are associated with CCA. CCA is a connective tissue disease characterized by arachnodactyly, contractures of major joints and progressive scoliosis [17]. These phenotypes are similar to the slender fingers and joint contractures observed in the proband and his father. Genetic analysis identified a novel heterozygous \( \text{FBN2} \) nonsense mutation (c.4108G > T; p.Glu1370*) in the proband and his affected father. However, this mutation was not found in his sister, who demonstrated a milder phenotype. These observations suggest a synergistic effect of these mutant alleles of two related but distinct genes, \( \text{COL1A2} \) and \( \text{FBN2} \), and this finding provides evidence for a digenic form of skeletal disorders.

In this report, a heterozygous mutation in \( \text{COL1A2} \) combined with another heterozygous mutation in \( \text{FBN2} \) simultaneously aggravates the skeletal clinical phenotype in individuals. The Reactome signal pathway database (https://reactome.org) and previous studies show that both \( \text{COL1A2} \) and \( \text{FBN2} \) are involved in the extracellular matrix organization pathway [11, 18], suggesting that both genes play an important role in the assembly and degradation of the extracellular matrix (ECM). It is well known that the extracellular matrix can send signals to cells to direct or regulate the transcription of certain mRNAs [19–21]. Therefore, we suspect that a mutation in one of the two genes, \( \text{COL1A2} \) and \( \text{FBN2} \), may affect the expression level of the other gene, but this requires further research.

Compared to monogenic inheritance, digenic inheritance does not follow the rules of Mendelian inheritance, so it is often underdiagnosed due to the difficulty of verifying the true synergistic effect. The members of the extracellular matrix structural constituent, \( \text{COL4A3}, \text{COL4A4} \) and \( \text{COL4A5} \), have been reported to be consistent with digenic inheritance and, together, lead to the occurrence of Alport syndrome [22–24]. \( \text{COL1A2} \) and \( \text{FBN2} \) are also members of the
extracellular matrix pathway. Thus, these two genes may be functionally related and may also have a synergistic effect.

Large-scale research projects in genetic diseases have indicated that massively parallel whole-genome/whole-exome sequencing can reveal a large number of new genes or new alleles that otherwise would be undetected by traditional sequencing methodologies [25]. At present, whole-exome sequencing based on next-generation sequencing technology is one of the most effective tools for the diagnosis of genetic diseases. Our results provide accurate genetic information for targeted treatment, genetic counselling and subsequent prenatal diagnosis for the patients in this family.

Conclusion
In conclusion, we successfully identified a mutation in exon 49 of COL1A2 (c.3304G > C; p.Gly1102Arg) and another novel heterozygous FBN2 mutation (c.4108G > T; p.Glu1370*) in this family. The novel variant expands the spectrum of mutations in the FBN2 gene. Furthermore, this is the first clinical report to identify patients carrying coexisting mutations in both the COL1A2 and FBN2 genes that contribute to more severe skeletal abnormalities. Furthermore, our segregation analysis indicated the possibility of synergistic effects between the COL1A2 and FBN2 genes.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12920-022-01296-8.

Acknowledgements
Not applicable.

Author contributions
MY, SL and HW designed the study. XX, BX and HX performed the experiments. JC and QX conducted data analysis. JC and QX wrote the article. All authors read and approved the final manuscript.

Funding
This work was supported by the National Key Research and Development Program of China (2021YFC1005303) and the Science and Technology Department of Sichuan Province, China (2021YFS0078). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
For the considerations about the security of human genetic resources and the confidentiality of participant, the data is not publicly available, but can be obtained from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The present study was approved by the Medical Ethics Committee of West China Second University Hospital (Sichuan University). Written informed consent was obtained from the patients and their parents, who agreed to join this study.

Consent for publication
All patients and their parents signed the informed consent during the counseling sessions and agreed to share their variant data in a reputable scientific journal. The patient's parents provided the written consent for the manuscript to be published. Informed consent from parents regarding data and clinical details for publication has been obtained.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Obstetrics and Gynecology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 2Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan, China. 3Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan, China.

Received: 29 October 2021 Accepted: 22 June 2022
Published online: 08 July 2022

References
1. Amor IB, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;2011:540178.
2. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377–85.
3. Ji CC, He J, Zhu BC. Advances in research on achondroplasia. Matern Child Health Care China. 2014;29(3):13.
4. Silence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.
5. Cohn DH, Apone S, Eyer DR, Starman BJ, Andreassen P, Charbonneau H, et al. Substitution of cysteine for glycine within the carboxyl-terminal telopeptide of the alpha 1 chain of type I collagen produces mild osteogenesis imperfecta. J Biol Chem. 1988;263:14605–7.
6. Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol. 2002;49:433–41.
7. Silence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–16.
8. Silence DO, Barlow KK, Garber AP, et al. Osteogenesis imperfecta type II delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet A. 2010;17(2):407–23.
9. Loeyes BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47:476–85.
10. Callewaert BL, Loeyes BL, Ficcadenti A, Vermeer S, Landgren M, Kroes HY, et al. Comprehensive clinical and molecular assessment of 32 probands with congenital contractual arachnodactyly: report of 14 novel mutations and review of the literature. Hum Mutat. 2009;30:334–41.
11. Smaldone S, Ramirez F. Fibroblasts and growth factors in bone physiology. Matrix Biol. 2016;52–54:191–7.
12. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint
consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

13. Budirmanok S, Intarak N, Theerapanon T, Yodsang M, Pomtavee T, Shotelersuk V. A novel mutation in COL1A2 leads to osteogenesis imperfecta/Ehlers-Danlos overlap syndrome with brachydactyly. Genes Dis. 2019;6:138–46.

14. Wenstrup RJ, Cohen DH, Cohen T, Byers PH. Arginine for glycine substitution in the triple-helical domain of the products of one alpha 2(I) collagen allele (COL1A2) produces the osteogenesis imperfecta type IV phenotype. J Biol Chem. 1988;263:7734–40.

15. Tsiouris A, Del MastropRod R, Sefaraz M, Lee B, Vitale E, Child AH, et al. Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractual arachnodactyly to the fibrillin genes on chromosomes 15 and 5. The International Marfan Syndrome Collaborative Study. N Engl J Med. 1992;326:905–9.

16. Putnam EA, Zhang H, Ramirez F, Milewicz DM. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractual arachnodactyly. Nat Genet. 1995;11:456–8.

17. Gupta PA, Putnam EA, Carmical SG, Kaitoi I, Steinmann B, Child A, et al. Ten novel FBN2 mutations in congenital contractual arachnodactyly: delineation of the molecular pathogenesis and clinical phenotype. Hum Mutat. 2002;19:39–48.

18. Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052.

19. Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest. 2018;128:45–53.

20. Rouxelle P, Montmasson M, Garnier C. Extracellular matrix contribution to skin wound re-epithelialization. Matrix Biol. 2019;75–76:12–26.

21. Yamada KM, Collink J, Cruz Walma DA, Doyle AD, Morales SG, Lu J, et al. Extracellular matrix dynamics in cell migration, invasion and tissue morphogenesis. Int J Exp Pathol. 2019;100:144–52.

22. Fallarini C, Baldassarri M, Trevisson E, Morbidoni V, La Manna A, Lazzarin R, et al. Alport syndrome: impact of digenic inheritance in patients management. Clin Genet. 2017;92:34–44.

23. Choi M, Anistan YM, Eckardt KU, Gollasch M, Nickel P. Possible digenic disease in a Caucasian family with COL4A3 and COL4A5 mutations. Nephron. 2019;141:213–8.

24. Gibson J, Fieldhouse R, Chan MM, Sadeghhi-Alavijeh O, Burnett L, Izz V, et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for alport syndrome. J Am Soc Nephrol. 2021;32:2273–90.

25. Beigh MM. Next-generation sequencing: the translational medicine approach from “bench to bedside to population.” Medicines. 2016;3(2):14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions